News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
119,146 Results
Type
Article (7139)
Company Profile (57)
Press Release (111950)
Section
Business (38144)
Career Advice (87)
Deals (5914)
Drug Delivery (8)
Drug Development (23607)
Employer Resources (12)
FDA (2968)
Job Trends (3558)
News (68555)
Policy (4595)
Tag
Academia (320)
Africa (81)
Alabama (18)
Alliances (11065)
Alzheimer's disease (109)
Antibody-drug conjugate (ADC) (40)
Approvals (2960)
Artificial intelligence (14)
Asia (10199)
Australia (1348)
Bankruptcy (53)
Best Places to Work (3128)
Biosimilars (14)
Biotechnology (48)
Breast cancer (21)
C2C Services and Suppliers (7257)
California (448)
Canada (164)
Cancer (228)
Career advice (74)
CAR-T (26)
Cell therapy (45)
China (49)
Clinical research (18923)
Collaboration (39)
Colorado (11)
Compensation (10)
Connecticut (19)
COVID-19 (291)
Data (57)
Delaware (13)
Diagnostics (1207)
Drug discovery (10)
Earnings (12450)
Employer resources (12)
Europe (18775)
Events (22046)
Executive appointments (38)
FDA (3008)
Florida (52)
Funding (29)
Gene therapy (12)
GLP-1 (89)
Government (459)
Healthcare (4016)
Hotbed/Location (82797)
Illinois (36)
Indiana (18)
Infectious disease (297)
Inflammatory bowel disease (17)
Interviews (11)
IPO (2913)
Job creations (482)
Job search strategy (70)
Layoffs (105)
Legal (466)
Liver cancer (28)
Lung cancer (61)
Lymphoma (11)
Maryland (95)
Massachusetts (378)
Medical device (825)
Medtech (825)
Mergers & acquisitions (2982)
Metabolic disorders (20)
Minnesota (44)
Neuroscience (128)
New Jersey (80)
New York (120)
NextGen Class of 2024 (940)
Non-profit (488)
North Carolina (114)
Northern California (223)
Obesity (10)
Ohio (21)
Opinion (24)
Ovarian cancer (12)
Pancreatic cancer (12)
Pennsylvania (80)
People (12462)
Pharmaceutical (11)
Phase I (7099)
Phase II (8003)
Phase III (6080)
Pipeline (36)
Postmarket research (470)
Preclinical (2185)
Prostate cancer (10)
Real estate (726)
Regulatory (3857)
Research institute (659)
Resumes & cover letters (11)
Series A (11)
South America (108)
Southern California (191)
Startups (752)
Texas (50)
United States (1684)
Vaccines (66)
Washington State (47)
Date
Today (2)
Last 7 days (120)
Last 30 days (486)
Last 365 days (10003)
2024 (6621)
2023 (10638)
2022 (13111)
2021 (13179)
2020 (10962)
2019 (8595)
2018 (6336)
2017 (7127)
2016 (6286)
2015 (6948)
2014 (4524)
2013 (3091)
2012 (3341)
2011 (3329)
2010 (3039)
119,146 Results for "clovis oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis
Clovis Oncology officially files for Chapter 11 bankruptcy.
December 12, 2022
·
3 min read
·
Alex Keown
Business
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177.
September 21, 2022
·
8 min read
Business
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to its Board of Directors.
June 10, 2024
·
3 min read
Deals
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Clovis Oncology, Inc. announced that it and certain of its subsidiaries have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware and will seek to sell their assets through a court supervised sales process.
December 12, 2022
·
5 min read
Drug Development
Clinical Catch-Up: Scandion Oncology, Edesa Biotech, Clovis & More
Scandion Oncology, Edesa, Clovis, Lexicon and Cytokinetics share a string of positive news from their clinical trials on heart failure, cancer, COVID-19 and ARDS.
October 3, 2022
·
5 min read
·
Vanessa Doctor, RN
Drug Development
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
Clovis Oncology, Inc. announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177.
October 17, 2022
·
10 min read
Deals
Clovis Axes 115 Employees, Warns of Potential Bankruptcy
Bankruptcy might be looming for embattled Clovis Oncology, the company warned Wednesday in a 10-Q filing. Clovis also revealed it has taken action to reduce its workforce by 115 employees.
November 9, 2022
·
2 min read
·
Heather McKenzie
Biotech Beach
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology, Inc. today announced its participation in Stifel 2024 Targeted Oncology Forum.
April 10, 2024
·
2 min read
Press Releases
Radionetics Oncology Enters Into Strategic Agreement With Lilly
Radionetics Oncology announced today the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals.
July 1, 2024
·
2 min read
BioMidwest
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
Clovis Oncology, Inc., announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA trial.
September 11, 2022
·
19 min read
1 of 11,915
Next